Bayer’s SUNHARBO® (asundexian), 50 mg tablets, the First and Only Factor XIa Inhibitor, Approved by the U.S. FDA to Reduce the Risk of Stroke in Adults With Recent Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack...

The approval follows a Phase 3 study showing a 26% reduction in ischemic stroke versus placebo alongside antiplatelet therapy.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

KEY FACTS

• The full indication for SUNHARBO^® (asundexian) is to reduce the risk of stroke in adults with recent non-cardioembolic ischemic stroke (National Institutes of Health Stroke Scale [NIHSS] ≤15) or high-risk transient ischemic attack (TIA) in combination with antiplatelet therapy.¹
• SUNHARBO is a first-in-class, once daily, Factor XIa inhibitor for secondary stroke prevention.¹
• Approximately one in five people who had a stroke will have another stroke within five years, and secondary strokes often cause more devastating outcomes than first strokes.²

WHIPPANY, N.J.--(BUSINESS WIRE)--

Bayer

Bayer’s SUNHARBO^® (asundexian), 50 mg tablets, the First and Only Factor XIa Inhibitor, Approved by the U.S. FDA to Reduce the Risk of Stroke in Adults With Recent Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack, in Combination With Antiplatelet Therapy

Bayer announced today that the U.S. Food and Drug Administration (FDA) has approved SUNHARBO^® (asundexian), 50 mg tablets, a first-in-class, once daily, Factor XIa inhibitor indicated in combination with antiplatelet therapy to reduce the risk of stroke in adults with recent non-cardioembolic ischemic stroke (NIHSS ≤15) or high-risk transient ischemic attack (TIA). Reducing the risk of a stroke after an initial event is often referred to as secondary stroke prevention. The recommended dosage of SUNHARBO is 50 mg once daily. SUNHARBO is the first approved medicine in the U.S. to target Factor XIa, representing a new approach to reducing the risk of ischemic stroke.¹

SUNHARBO is an inhibitor of Factor XIa. Factor XIa inhibition reduces amplification of thrombin generation. In preclinical models, Factor XIa inhibition targets more pathological clotting (thrombosis) with lesser impact on normal clotting response (hemostasis).¹

BAYER EXECUTIVE COMMENTARY

"For decades, Bayer has worked to advance care in cardiovascular and cerebrovascular diseases. Today’s approval offers stroke patients a novel treatment option to reduce their risk of stroke, building on our company’s legacy to develop first-in-class products that address significant health challenges,” said Nelson Ambrogio, President of Bayer U.S. Pharmaceuticals. “We are proud to bring the first approved Factor XIa inhibitor to market in the U.S. for secondary stroke prevention.”

WHY SECONDARY STROKE RISK REDUCTION MATTERS

• Stroke is the fifth leading cause of death in the U.S.³
• Each year, approximately 795,000 people in the U.S. will experience a stroke. Of these, approximately 87% are ischemic and 23% are recurrent.³
• Approximately one in 10 stroke survivors will have another stroke within one year, and one in five will have another stroke within five years.²

EXPERT COMMENTARY

“For those who survive a stroke, the risk of another potentially devastating event is highest in the days and weeks after the initial event, and that risk persists over time,” said Ashkan Shoamanesh, M.D., Co-principal Investigator of the OCEANIC-STROKE clinical study and Senior Scientist at Population Health Research Institute (PHRI), a joint institute of Hamilton Health Sciences and McMaster University (Ontario, Canada). “I believe SUNHARBO introduces an important new addition to post-stroke care that can be used to help patients reduce the risk of a secondary stroke.”

OCEANIC-STROKE CLINICAL TRIAL RESULTS

SUNHARBO was approved based on results from the pivotal Phase 3 OCEANIC-STROKE study where SUNHARBO was studied versus placebo in adults after a non-cardioembolic ischemic stroke (NIHSS ≤15) or high-risk transient ischemic attack, both in combination with antiplatelet therapy. The study randomized 12,327 patients to receive either SUNHARBO (N=6,162), or placebo (N=6,165). The mean age at enrollment was 68 years. The primary endpoint was time to first occurrence of ischemic stroke.¹

• SUNHARBO significantly reduced ischemic stroke by 26% compared to placebo (6.2% vs. 8.4%; HR 0.74; 95% CI, 0.65–0.84; P<0.0001).⁴
• The rate of major bleeding was similar for SUNHARBO compared to placebo (1.6 vs. 1.5 per 100-person years; HR 1.1; 95% CI, 0.8–1.4).¹
• SUNHARBO also significantly reduced the risk of all strokes (ischemic and hemorrhagic) versus placebo (6.6% vs. 8.8%; HR 0.74; 95% CI, 0.65–0.84; P<0.0001). The result of this secondary endpoint was primarily driven by reduction of ischemic stroke.¹
• SUNHARBO reduced the composite of cardiovascular death, myocardial infarction (MI) or stroke (9.2% vs. 11.1%; HR 0.83; 95% CI, 0.74–0.92). The result of this secondary endpoint was primarily driven by reduction of ischemic stroke.¹
• The most frequently reported (>3%) adverse reaction in the SUNHARBO treated patients was diarrhea (3.4% vs. 2.8% in the SUNHARBO and placebo groups, respectively).¹
• The rate of gastrointestinal bleeding was higher in the SUNHARBO group compared to placebo (2.7 vs 2.1 per 100 patient-years; HR 1.3; 95% CI, 1.0–1.6).¹
• Clinical data indicate that SUNHARBO is associated with elevated hepatic enzymes. The majority (74%) of the hepatic enzyme increased events were reported as mild in severity.¹

This approval marks the first for a Factor XIa inhibitor in the U.S. Bayer anticipates that SUNHARBO will begin shipping in mid-to-late November and is expected to become available for hospitals and pharmacies to order across the U.S. shortly thereafter.

Bayer is committed to making SUNHARBO accessible. If a patient cannot afford their prescription, Bayer may be able to help. Eligible patients may receive their Bayer prescription medicine at no cost through the Bayer U.S. Patient Assistance Foundation. For more information, please visit www.patientassistance.bayer.us or call to speak with a member of Bayer’s team at 1-866-2BUSPAF (228-7723).

As of November 2026, SUNHARBO is currently under review by the European Medicines Agency (EMA) and Japan's Ministry of Health, Labour and Welfare (MHLW). SUNHARBO was approved by China's National Medical Products Administration (NMPA) on October 26, 2026.

About SUNHARBO^® (asundexian)

SUNHARBO is a once-daily, first-in-class, oral Factor XIa inhibitor approved by the U.S. FDA and indicated in combination with antiplatelet therapy to reduce the risk of stroke in adults with recent non-cardioembolic ischemic stroke (NIHSS≤15) or high-risk transient ischemic attack (TIA). SUNHARBO is the first approved Factor XIa inhibitor in the U.S. and represents the first medicine in a new class designed to target Factor XIa. SUNHARBO is an inhibitor of Factor XIa. Factor XIa inhibition reduces amplification of thrombin generation. In preclinical models, Factor XIa inhibition targets more pathological clotting (thrombosis) with lesser impact on normal clotting response (hemostasis).¹

SUNHARBO was approved based on results from the pivotal Phase 3 OCEANIC-STROKE study where SUNHARBO significantly reduced ischemic stroke in patients after a recent non-cardioembolic ischemic stroke or high-risk transient ischemic attack compared to placebo (6.2% vs. 8.4%; HR 0.74; 95% CI, 0.65–0.84; P<0.0001), both in combination with antiplatelet therapy.¹

For additional information about SUNHARBO, healthcare professionals may visit SUNHARBOhcp.com. Please see the full prescribing information.

INDICATION

SUNHARBO^® is indicated in combination with antiplatelet therapy to reduce the risk of stroke in adults with recent non-cardioembolic ischemic stroke (NIH Stroke Scale ≤ 15) or high-risk transient ischemic attack (TIA).

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS and WARNINGS & PRECAUTIONS

None.

ADVERSE REACTIONS

Bleeding

• The rate of International Society on Thrombosis and Haemostasis (ISTH) major bleeding was similar between SUNHARBO and placebo groups (1.6 vs. 1.5 per 100 patient-years).
• The rate of ISTH major bleeding events within 90 days of treatment initiation was 4.5 vs. 3.1 per 100 patient-years in the SUNHARBO and placebo groups, respectively.
• In patients planned to receive DAPT, the rate of ISTH major bleeding events was 1.9 vs. 1.5 per 100 patient-years in the SUNHARBO and placebo groups, respectively.
• Among patients older than 75 years, the rate of ISTH major bleeding was 2.6 vs. 1.7 per 100 patient-years in the SUNHARBO and placebo groups, respectively.
• In the high-risk TIA subgroup, the rate of ISTH major bleeding was 2.9 vs. 1.0 per 100 patient-years in the SUNHARBO and placebo groups, respectively.
• The rate of gastrointestinal (GI) bleeding was higher in the SUNHARBO compared to placebo group (2.7 vs. 2.1 per 100 patient-years). The majority of GI bleeding events in the SUNHARBO group (74%) were clinically relevant non-major or minor bleeding, and the most frequent bleeding site was of rectal origin.

Diarrhea

• The most frequently reported (> 3%) adverse reaction in SUNHARBO-treated patients was diarrhea.

Hepatic Enzyme Increased

• SUNHARBO is associated with elevated hepatic enzymes. Substantial cholestatic liver injury or serious liver injury with jaundice were each reported in less than 0.02% of SUNHARBO-treated patients.

DRUG INTERACTIONS

• P-glycoprotein (P-gp) substrates - Concomitant use of SUNHARBO increased the exposure to digoxin. For digoxin and sensitive P-gp substrates where minimal concentration changes may increase the risk of adverse reactions, follow the recommendation in their approved product labeling.
• Combined P-gp and strong CYP3A4 inducers - Avoid concomitant use with combined P-gp and strong CYP3A4 inducers, which decreases SUNHARBO exposure and may lead to loss of efficacy.

USE IN SPECIFIC POPULATIONS

Pregnancy

• There are risks to the mother associated with untreated non-cardioembolic ischemic stroke or TIA and risk of bleeding in the mother and fetus or neonate associated with use of anticoagulants during pregnancy.

Lactation

• Breastfeeding is not recommended during treatment with SUNHARBO and for 5 days after the last dose due to the potential for serious adverse reactions in nursing infants, including bleeding.

Hepatic Impairment

• Patients with moderate to severe hepatic impairment (Child-Pugh B and C) may have intrinsic coagulation abnormalities and use of SUNHARBO in these patients is not recommended.

For additional important risk and use information, please see the full Prescribing Information.

You are encouraged to report side effects or quality complaints of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

About Bayer’s Stroke Franchise

Bayer is a leader in cardiovascular (CV) and cerebrovascular diseases, with a longstanding legacy of scientific innovation in the prevention and treatment of thrombotic conditions. Building on this heritage, Bayer is advancing innovative approaches to help address unmet needs in stroke, with a focus on the area of secondary stroke prevention and research into new pathways, including Factor XIa. Bayer aims to help shape the future of stroke care with products strategically positioned to help address critical unmet needs and drive significant long-term value. Bayer is working alongside the stroke community to better understand unmet needs and support patients and care partners across the stroke journey.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to support efforts to master major challenges presented by a growing and aging global population and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2025, the Group employed around 88,000 people and had sales of 45.6 billion euros. R&D expenses amounted to 5.8 billion euros.

Find more information at: Health for all, Hunger for none | Bayer United States
Follow us on Facebook: Bayer
Follow us on LinkedIn: Bayer | Pharmaceuticals
Follow us on X: BayerUS
Follow us on Instagram: BayerUS

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

References:

1. SUNHARBO® (asundexian) [Prescribing Information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals, Inc.; October 2026.
2. Kolmos M, et al. Recurrent ischemic stroke–a systematic review and meta-analysis. Journal of Stroke and Cerebrovascular Diseases. 2021 Aug 1;30(8):105935.
3. Martin SS, et al. Circulation. 2024;149(8):e347-e913.
4. Sharma M, Dong Q, Hirano T, et al. Asundexian for secondary stroke prevention. N Engl J Med. 2026;394:1467-1479. doi:10.1056/NEJMoa2513880.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20261021770347/en/

Contact for U.S. media inquiries:
Sarra Herzog, phone +1 862-460-8764
Email: sarra.herzog@bayer.com

Contact for investor inquiries:
Bayer Investor Relations Team, phone +49 214 30-72704
Email: ir@bayer.com
www.bayer.com/en/investors/ir-team

Source: Bayer

Key Terms

factor xia inhibitor medical

A factor XIa inhibitor is a class of medicine that blocks activated factor XI, a protein that helps blood form clots; by slowing one step in the clotting chain reaction it reduces the chance of dangerous clots such as strokes or post-surgery thrombosis. Investors watch these drugs because they promise the market value of traditional blood thinners but with a potentially lower risk of bleeding — like a smarter brake that aims to stop accidents without causing spills — so clinical results and approvals can materially affect sales and company valuations.

thrombosis medical

Thrombosis is the formation of a blood clot inside a blood vessel that can block normal blood flow, like a plaster clogging a pipe. It matters to investors because clotting events affect the safety profile and regulatory review of drugs, medical devices and treatments, can drive costly litigation or recalls, and influence healthcare demand and company valuations tied to patient outcomes and product approvals.

hemostasis medical

Hemostasis is the body’s process for stopping bleeding, using a coordinated set of responses that form clots and seal damaged vessels—think of it as the body's natural emergency patch and repair crew. It matters to investors because drugs, medical devices, and diagnostics that influence hemostasis can affect patient outcomes, regulatory approval paths, and market demand for treatments of bleeding disorders or clot-related conditions, so advances or safety issues can materially impact company value.

p-glycoprotein medical

P-glycoprotein is a protein in cell membranes that works like a molecular bouncer, actively pumping certain drugs and chemicals out of cells and controlling how much of a medicine reaches organs such as the brain and gut. For investors, P-glycoprotein matters because it can reduce a drug's absorption, cause interactions with other medicines, or make cancers resistant to treatment, all of which affect a drug's effectiveness, dosing, safety profile and regulatory or commercial prospects.

cyp3a4 inducers medical

CYP3A4 inducers are drugs or other substances that increase the production or activity of the liver enzyme cytochrome P450 3A4, causing the enzyme to clear substrates faster than normal. They act by up‑regulating the gene expression or stabilizing the enzyme, which typically lowers blood concentrations and shortens the duration of action of medicines metabolized by CYP3A4. Induction usually develops over days to weeks of exposure and likewise fades gradually after the inducer is stopped, so the effect on co‑administered drugs is delayed in onset and offset.